Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.

中文翻译：

---

利伐沙班：在心血管疾病管理中的作用扩大－文献综述

直接口服抗凝剂（DOAC）被广泛用于预防非瓣膜性房颤的中风，深静脉血栓形成和肺栓塞的治疗，以及经美国食品药品监督管理局批准的髋关节和膝关节手术后的预防措施。在过去的十年中，对DOAC进行了各种适应症的研究。这篇综述的重点是利伐沙班，一种Xa因子抑制剂，它以循证医学的形式广泛用于急性医学疾病中的冠状动脉疾病，外周动脉疾病，心力衰竭，恶性肿瘤和深静脉血栓形成的预防。